Bli medlem
Bli medlem

Du är här


DSM N.V. : DSM Q4 2015 results


* Q4 Group: net sales up 6% to €1,926m and EBITDA up 3% to €261m
* Q4 Nutrition: 7% organic growth with strong volume growth in both Animal
and Human Nutrition
* Q4 EBITDA: Nutrition up 3%, Performance Materials up 13%
* Strong Q4 operating cash flow of €313m supported by working capital
* 2015: solid performance with Group net sales of €7,722m and EBITDA up 4% to
* Proposed dividend stable at €1.65 per ordinary share

Key figures and indicators (continuing operations)

| in € million Q4 2015 Q4 2014 % Change Volume Price/mix FX Other |
| Sales 1,926 1,811 6% 3% -2% 4% 1% |
| Nutrition 1,264 1,124 12% 7% 0% 3% 2% |
| Performance Materials 601 618 -3% -1% -7% 5% |
| EBITDA 261 254 3% |
| Nutrition 206 200 3% |
| Performance Materials 90 80 13% |
| ROCE (%)1 7.6% 8.2% |
1Based on full year

CEO statement
Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented:"DSM's
fourth quarter performance, slightly ahead of expectations, was
encouraging. We are particularly pleased with our progress in Nutrition,
where both Animal and Human Nutrition delivered strong organic growth.
Performance Materials continued to benefit from improved margins. In
addition, our focus on cash flow and working capital efficiency contributed
to a strong operating cash flow of
€313 million.

This good progress in Q4 completes a year in which we achieved solid results.
We delivered strong organic growth in Nutrition despite lower vitamin E
prices. Cost savings and good margin management helped drive higher margins
in Performance Materials, which also benefited from lower input costs.
Currencies, while being a mixed bag, had a favorable effect overall despite
the strengthening of the Swiss franc.

We expect to make further progress with our growth initiatives in 2016 both in
Nutrition and Performance Materials although the macro-economic context
remains challenging. These will be underpinned by our group-wide cost and
productivity improvement programs as well as our disciplined focus on capital
allocation and working capital. We are on track with these initiatives which
will help drive improved profitability and return on capital that we target
with our Strategy 2018

Outlook 2016

DSM aims to deliver increased full-year EBITDA and ROCE in line with the targets set out in its Strategy 2018:Driving Profitable Growth

Note for editors: for the full text of the press release, see enclosed pdf or clickhere>
Contact Information
| Investor Relations Dave Huizing |
| |
| t. +31 (0) 45 578 28 64 |
| |
| |
| Media Relations Stephen Hufton |
| |
| t. +31 (0) 45 578 7029 |
| |

Additional Information

Today DSM will hold a conference call formedia
from 08:00 to 08:30 and a conference call from forinvestors and analysts
from 09:00 to 10:00. Details on how to access these calls can be found on the DSM website,

Press release-pdf
Presentation to Investors-pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM N.V. via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.